Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Severe weather warning in your area. Please stay indoors and stay safe. Read more
regimen-monograph
CISP
A - Regimen Name
CISP Regimen
CISplatin
Disease Site
Gynecologic
Intent
Palliative
Regimen Category
Archived : No longer in use and listed for reference purposes only, although the use of such a regimen may be appropriate in a situation where a Standard Regimen cannot be used for clinical reasons. Note: The Disease Site Group considers this regimen archived. It is listed for historical reference only and is no longer updated.
Rationale and Uses
Treatment of platinum-sensitive recurrent ovarian cancer (with a progression-free interval ≥ 6 months since the last line of platinum-based therapy), if combination platinum-based chemotherapy is contraindicated
B - Drug Regimen
| CISplatin
(Round to nearest 1 mg) |
50-75 mg /m² | IV | Day 1 |
|
(Given in hospital or cancer centre)
|
|||
E - Dose Modifications
Doses should be modified according to the protocol by which the patient is being treated. The following recommendations are in use at some centres.
Dosage with toxicity
Worst Toxicity in Previous Cycle |
Dose for next cycle*
|
Grade 4 platelets, grade 4 ANC ≥ 5 days, thrombocytopenic bleeding or febrile neutropenia |
↓ 25%
|
Grade 2 Neurotoxicity /ototoxicity |
↓ 25%
|
|
Grade 3 or 4 Neurotoxicity/ototoxicity
|
Discontinue
|
Other grade 3 non-hematologic/organ toxicity |
↓ 25%
|
|
Other grade 4 non-hematologic/organ toxicity
|
Discontinue
|
Hemolysis, optic neuritis, arterial thromboembolism, severe hypersensitivity reactions, grade 3 or 4 ↑ LFTs |
Discontinue
|
* do not retreat until platelets ≥ 100 x109/L, ANC ≥ 1.5 x109/L, toxicity has recovered to ≤ grade 2 (grade 1 for neurotoxicity) and creatinine ≤ ULN |
|
Hepatic Impairment
No adjustment required
Renal Impairment
In general, renal function should have normalized before patients are retreated. If continued treatment is considered to be mandatory, the following dose modifications could be considered at the physician's discretion:
|
Creatinine clearance
|
% previous dose
|
|
46-60
|
75%
|
|
30-45
|
50%
|
|
<30
|
Discontinue
|
F - Adverse Effects
Refer to CISplatin drug monograph(s) for additional details of adverse effects
| Most Common Side Effects | Less Common Side Effects, but may be Severe or Life Threatening |
|
|
H - Drug Administration and Special Precautions
Refer to CISplatin drug monograph(s) for additional details
I - Recommended Clinical Monitoring
Recommended Clinical Monitoring
- Audiogram; as clinically indicated
- CBC; baseline and regular
- Electrolytes, including magnesium, sodium, potassium, phosphate and calcium; baseline and regular
- Renal function tests; baseline and regular
- Clinical toxicity assessment (infection, bleeding, nausea/vomiting, neurotoxicity, ototoxicity); at each visit
- Grade toxicity using the current NCI-CTCAE (Common Terminology Criteria for Adverse Events) version
Suggested Clinical Monitoring
- Audiogram; baseline and periodic
- Liver function tests; baseline and regular
back to top
K - References
Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099-106.
April 2012: Modified regimen category
PEBC Advice Documents or Guidelines
M - Disclaimer
Regimen Abstracts
A Regimen Abstract is an abbreviated version of a Regimen Monograph and contains only top level information on usage, dosing, schedule, cycle length and special notes (if available). It is intended for healthcare providers and is to be used for informational purposes only. It is not intended to constitute or be a substitute for medical advice, and all uses of the Regimen Abstract are subject to clinical judgment. Such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability, and Cancer Care Ontario disclaims all liability for the use of this information, and for any claims, actions, demands or suits that arise from such use.
Information in regimen abstracts is accurate to the extent of the ST-QBP regimen master listings, and has not undergone the full review process of a regimen monograph. Full regimen monographs will be published for each ST-QBP regimen as they are developed.
Regimen Monographs
Refer to the New Drug Funding Program or Ontario Public Drug Programs websites for the most up-to-date public funding information.
The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects of a particular drug, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for a given condition. The information in the Formulary is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.
The format and content of the drug monographs, regimen monographs, appendices and symptom management information contained in the Formulary will change as they are reviewed and revised on a periodic basis. The date of last revision will be visible on each page of the monograph and regimen. Since standards of usage are constantly evolving, it is advised that the Formulary not be used as the sole source of information. It is strongly recommended that original references or product monograph be consulted prior to using a chemotherapy regimen for the first time.
Some Formulary documents, such as the medication information sheets, regimen information sheets and symptom management information (for patients), are intended for patients. Patients should always consult with their healthcare provider if they have questions regarding any information set out in the Formulary documents.
While care has been taken in the preparation of the information contained in the Formulary, such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability.
CCO and the Formulary’s content providers shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Formulary or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the Formulary does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person’s use of the information in the Formulary.
Last Updated: July 21, 2026
